42 assets in Lymphoplasmacytic Lymphoma

Therapeutic assets addressing Lymphoplasmacytic Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rituximab Lymphoplasmacytic Lymphoma	Memorial Sloan Kettering Cancer Center	P3	BB (69)
Cyclophosphamide Lymphoplasmacytic Lymphoma	Affiliated Hospital to Academy of Military Medical Sciences	P3	BB (67)
Bendamustine Lymphoplasmacytic Lymphoma	City of Hope Medical Center	P3	BB (66)
Fludarabine Lymphoplasmacytic Lymphoma	Affiliated Hospital to Academy of Military Medical Sciences	P3	BB (66)
Adriamycin Lymphoplasmacytic Lymphoma	National Cancer Institute (NCI)	P3	BB (65)
Prednisone Lymphoplasmacytic Lymphoma	National Cancer Institute (NCI)	P3	BB (65)
Ibrutinib Lymphoplasmacytic Lymphoma	National Cancer Institute (NCI)	P2	B (63)
Obinutuzumab Lymphoplasmacytic Lymphoma	Emory University	P2	B (63)
(+)-Vincristine Lymphoplasmacytic Lymphoma	Emory University	P3	B (62)
Lenalidomide Lymphoplasmacytic Lymphoma	Yazeed Sawalha	P1/2	B (60)
Vincristine Sulfate Lymphoplasmacytic Lymphoma	National Cancer Institute (NCI)	P2/3	B (60)
Cyclosporin A Lymphoplasmacytic Lymphoma	Fred Hutchinson Cancer Center	P2	B (59)
Azacitidine Lymphoplasmacytic Lymphoma	National Cancer Institute (NCI)	P2/3	B (58)
Busulfanum Lymphoplasmacytic Lymphoma	Masonic Cancer Center, University of Minnesota	P2	B (57)
Melphalan Lymphoplasmacytic Lymphoma	H. Lee Moffitt Cancer Center and Research Institute	P2	B (57)
Nivestim Lymphoplasmacytic Lymphoma	Fred Hutchinson Cancer Center	P2	B (57)
Tacrolimus Lymphoplasmacytic Lymphoma	Masonic Cancer Center, University of Minnesota	P2	B (57)
Thiotepa Lymphoplasmacytic Lymphoma	Fred Hutchinson Cancer Center	P2	B (57)
Recombinant Human Hyaluronidase Lymphoplasmacytic Lymphoma	National Cancer Institute (NCI)	P2/3	CCC (55)
Acalabrutinib Lymphoplasmacytic Lymphoma	Emory University	P2	CCC (53)
Iopofosine (¹³¹I) Lymphoplasmacytic Lymphoma	Cellectar Biosciences, Inc.	P2	CCC (53)
Mgta-456 Lymphoplasmacytic Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Pirtobrutinib Lymphoplasmacytic Lymphoma	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Treosulfan Lymphoplasmacytic Lymphoma	Fred Hutchinson Cancer Center	P2	CCC (53)
Venetoclax Lymphoplasmacytic Lymphoma	AbbVie	P2	CCC (53)
Zanubrutinib Lymphoplasmacytic Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Lymphoplasmacytic Lymphoma	City of Hope Medical Center	P1/2	CCC (50)
Pacritinib Lymphoplasmacytic Lymphoma	Shayna Sarosiek, MD	P2	CCC (50)
mdx2003 Lymphoplasmacytic Lymphoma	ModeX Therapeutics, An OPKO Health Company	P1/2	CC (45)
Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tn/Mem-Enriched T-Lymphocytes Lymphoplasmacytic Lymphoma	City of Hope Medical Center	P1	CC (43)
Bcma-Cd19 Ccar T Cells Lymphoplasmacytic Lymphoma	iCell Gene Therapeutics	P1	CC (43)
Etoposide Lymphoplasmacytic Lymphoma	City of Hope Medical Center	P1	CC (43)
Pevonedistat Lymphoplasmacytic Lymphoma	City of Hope Medical Center	P1	CC (43)
q702 Lymphoplasmacytic Lymphoma	Mayo Clinic	P1	CC (43)
Ublituximab Lymphoplasmacytic Lymphoma	Yazeed Sawalha	P1	CC (42)
cd22 car-t Lymphoplasmacytic Lymphoma	Stanford University	P1	CC (41)
Copanlisib Lymphoplasmacytic Lymphoma	City of Hope Medical Center	P1	CC (41)
Hmpl-760 Lymphoplasmacytic Lymphoma	Hutchmed	P1	CC (41)
Sgr-1505 Lymphoplasmacytic Lymphoma	Schrödinger, Inc.	P1	CC (41)
car19bcma-t cells Lymphoplasmacytic Lymphoma	Affiliated Hospital to Academy of Military Medical Sciences	Early P1	C (39)
64Cu-LLP2A Lymphoplasmacytic Lymphoma	Washington University School of Medicine	Early P1	C (38)
Umbralisib Lymphoplasmacytic Lymphoma	Yazeed Sawalha	P1	C (34)